Similar articles

• Pharmacokinetics and pharmacodynamics during treatment with the omeprazole 20 mg enteric-coated tablet and 20 mg capsule in asymptomatic duodenal ulcer patients.

  Thomson AB, Kirdeikis P, Lastiwka R, Röhss K, Sinclair P, Olofsson B. Thomson AB, et al. Can J Gastroenterol. 1997 Nov-Dec;11(8):657-60. doi: 10.1155/1997/910471. Can J Gastroenterol. 1997. PMID: 9459044 Clinical Trial.
• Influence of food on the bioavailability of an enteric-coated tablet formulation of omeprazole 20 mg under repeated dose conditions.

  Thomson AB, Sinclair P, Matisko A, Rosen E, Andersson T, Olofsson B. Thomson AB, et al. Can J Gastroenterol. 1997 Nov-Dec;11(8):663-7. doi: 10.1155/1997/830856. Can J Gastroenterol. 1997. PMID: 9459045 Clinical Trial.
• [Omeprazol and ezomeprazol pharmacokinetics, duration of antisecretory effect, and reasons for their probable changes in duodenal ulcer].

  Serebrova SIu, Starodubtsev AK, Pisarev VV, Kondratenko SN, Vasilenko GF, Dobrovol'skiĭ OV. Serebrova SIu, et al. Eksp Klin Gastroenterol. 2009;(4):86-92. Eksp Klin Gastroenterol. 2009. PMID: 19960999 Clinical Trial. Russian.
• Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole.

  Sharma VK. Sharma VK. Am J Health Syst Pharm. 1999 Dec 1;56(23 Suppl 4):S18-21. doi: 10.1093/ajhp/56.suppl_4.S18. Am J Health Syst Pharm. 1999. PMID: 10597120 Review.
• [Comparative study of proton pump inhibitors].

  Herszényi L, Tulassay Z. Herszényi L, et al. Orv Hetil. 2001 Sep 9;142(36):1953-61. Orv Hetil. 2001. PMID: 11680100 Review. Hungarian.